Polymeric and lipid-based drug delivery systems for treatment of glioblastoma multiforme

被引:38
作者
Duwa, Ramesh [1 ]
Emami, Fakhrossadat [1 ]
Lee, Sooyeun [1 ]
Jeong, Jee-Heon [2 ]
Yook, Simmyung [1 ]
机构
[1] Keimyung Univ, Coll Pharm, Daegu 42601, South Korea
[2] Yeungnam Univ, Coll Pharm, Gyongsan 38541, Gyeongbuk, South Korea
基金
新加坡国家研究基金会;
关键词
Glioblastoma multiforme; Polymeric nanoparticles; Nanomedicine; Polymeric; Hydrogel; Lipid-based nanoparticles; CHITOSAN-BASED NANOPARTICLES; LOADED PLGA NANOPARTICLES; HIGH-GRADE GLIOMAS; INTERSTITIAL CHEMOTHERAPY; THERMOREVERSIBLE GELATION; BRAIN-TUMORS; INJECTABLE HYDROGELS; LOCAL CHEMOTHERAPY; SUSTAINED-RELEASE; RADIATION-THERAPY;
D O I
10.1016/j.jiec.2019.06.050
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Glioblastoma multiforme (GBM) is the most aggressive, malignant brain tumor found in adults, and has a short median survival time (MST). GBM is a heterogeneous group of brain tumors, is highly prone to develop resistance and likely to recur. In the context of GBM, the delivery of anti-cancer drugs is challenging because the blood brain barrier (BBB) restricts the passage of small molecules. Currently, nanomedicines based on liposomes, micelles, polymeric nanoparticles, and microparticles have attracted much attention, because they can cross the BBB and deliver anti-cancer drugs specifically to brain tumors. In this context, hydrogel-based systems incorporating nanoparticles, implantable carmustine wafers, microspheres, and lipid-based nanoparticles now appear to offer more effective, safer treatment strategies than conventional chemotherapeutic regimens. This review describes different polymeric hydrogel, chitosan, dendrimers, wafers, microspheres, and lipid-based nanoparticles like liposomes and solid-lipid nanoparticles that offers prominent strategies for the treatment and diagnosis of GBM. (C) 2019 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:261 / 273
页数:13
相关论文
共 181 条
[1]   Dendrimers: synthesis, applications, and properties [J].
Abbasi, Elham ;
Aval, Sedigheh Fekri ;
Akbarzadeh, Abolfazl ;
Milani, Morteza ;
Nasrabadi, Hamid Tayefi ;
Joo, Sang Woo ;
Hanifehpour, Younes ;
Nejati-Koshki, Kazem ;
Pashaei-Asl, Roghiyeh .
NANOSCALE RESEARCH LETTERS, 2014, 9 :1-10
[2]   Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection [J].
Akbar, Umar ;
Jones, Terreia ;
Winestone, Jon ;
Michael, Madison ;
Shukla, Atul ;
Sun, Yichun ;
Duntsch, Christopher .
JOURNAL OF NEURO-ONCOLOGY, 2009, 94 (02) :203-212
[3]  
Alavi M, 2017, ADV PHARM BULL, V7, P3, DOI 10.15171/apb.2017.002
[4]   Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[5]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[6]   Stem cell based glioblastoma gene therapy [J].
Altaner, C. ;
Altanerova, V. .
NEOPLASMA, 2012, 59 (06) :756-760
[7]   Immunotherapeutic advancements for glioblastoma [J].
Ampie, Leonel ;
Woolf, Eric C. ;
Dardis, Christopher .
FRONTIERS IN ONCOLOGY, 2015, 5
[8]   Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation [J].
Ananta, Jeyarama S. ;
Paulmurugan, Ramasamy ;
Massoud, Tarik F. .
NEUROLOGICAL RESEARCH, 2016, 38 (01) :51-59
[9]  
[Anonymous], 2008, NEUROSURGERY
[10]  
[Anonymous], 2016, Asian J. Pharm. Clin. Res